Log in
Enquire now
‌

US Patent 11986509 Oligosaccharide formulations of kappa opioid receptor agonists

Patent 11986509 was granted and assigned to Cara Therapeutics on May, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Cara Therapeutics
Cara Therapeutics
0
Current Assignee
Cara Therapeutics
Cara Therapeutics
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
119865090
Patent Inventor Names
Stephen J. O'Connor0
Bryan R. Wilson0
Date of Patent
May 21, 2024
0
Patent Application Number
172049860
Date Filed
March 18, 2021
0
Patent Citations
‌
US Patent 8664178 Peptide pharmaceutical for oral delivery
0
‌
US Patent 9302010 Stable formulations for parenteral injection of peptide drugs
0
‌
US Patent 9399017 Peptide pharmaceutical for oral delivery
0
‌
US Patent 11033629 Oral formulations of kappa opioid receptor agonists
0
‌
US Patent 10028916 Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use
0
‌
US Patent 7402564 Synthetic peptide amides
0
‌
US Patent 7785631 Solid dose delivery vehicle and methods of making same
0
‌
US Patent 7956028 Protein stabilization formulations
0
...
Patent Primary Examiner
‌
Robert A Wax
0
CPC Code
‌
A61K 9/4808
0
‌
A61K 9/5089
0
‌
A61K 31/40
0
‌
A61K 9/1623
0
‌
A61K 9/1617
0
‌
A61K 38/07
0
‌
A61K 31/485
0
‌
A61K 9/1694
0
Patent abstract

The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist, an oligosaccharide stabilizing agent and an optional absorption enhancer. The kappa opioid receptor agonist may be coated with, embedded in or mixed with an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists, the oligosaccharide and the absorption enhancer of the invention. The invention further provides methods of manufacture of the formulations and methods of their use for the prophylaxis, inhibition and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation. The methods of use include administering to the mammal the formulation of the kappa opioid receptor agonist, oligosaccharide and optional absorption enhancers.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11986509 Oligosaccharide formulations of kappa opioid receptor agonists

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.